For the fourth quarter, the period ended Dec. 31, the Kalamazoo-based medical technologies company reported net earnings of $386 million, a 43 percent increase over $270 million in reported net earnings during fourth-quarter 2012.

It reported net earnings of $1 billion for the full year, a 22.5 percent decrease from $1.29 billion full year 2012.

On a per-share basis, it reported diluted net earnings of $1.01 for the quarter (up 42.3 percent) and $2.63 per diluted share for the full year (down 22.4 percent).

Excluding the impact of one-time events and charges, the company saw adjusted net earnings of $469 million for the quarter, a 7.6 percent increase over adjusted net earnings in fourth-quarter 2012. It logged $1.6 billion in adjusted net earnings for the year, a 3.6 percent increased over fiscal 2012.

Adjusted net earnings per share of $1.23 for the quarter (fully diluted) were up 7.9 percent and beat analysts’ forecasts of $1.22 per share. Adjusted diluted earnings per share for the full year were $4.23 increased, up 3.9 percent.

The medical technologies company reported net sales of $2.47 billion for the quarter, up 5.6 percent from fourth-quarter 2012 and better than analysts’ forecasts of $2.43 billion.

The maker of hospital beds, orthopedic implants and surgical devices reported full-year net sales of $9 billion, up 4.2 percent from $8.6 billion a year ago.

According to company officials, net sales during the quarter grew 7.3 percent due to increased unit volume and changes in product mix. They attributed 1.5 percent growth to acquisitions. But they noted that net sales for the quarter “were unfavorably impacted by 1.4 percent due to changes in price and 1.8 percent due to the unfavorable impact of foreign currency exchange rates on net sales."

"We are pleased with our organic sales growth and operational earnings achieved in 2013,” Stryker President and Chief Executive Officer Kevin A. Lobo said in a press release. “With our broad-based product portfolio and commitment to innovation and globalization we are well positioned to build on this momentum in 2014.”

Management said it expects organic sales growth of 4.5 to 6 percent for 2014 and “if foreign currency exchange rates hold near current levels, we expect net sales in the first quarter and full year of 2014 to be negatively impacted by less than 1 percent.”

The company forecasts adjusted net earnings in the range of $4.75 to $4.90 per share, excluding amortization of intangible assets.

Reported net earnings included charges associated with recalls for the Rejuvenate, ABG II and Neptune, and for charges related to acquisition of the neurovascular division of Boston Scientific Corp., Surpass Medical Ltd.,Trauson Holdings Company Limited and Mako Surgical Corp.